Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 19/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5456557 | 0.79 | LMNA (0.65) | TRPV1 | |
| SCHEMBL3247476 | 0.78 | GALR2 (0.59) | TRPV1 | |
| SCHEMBL3243408 | 0.77 | GALR2 (0.81) | TRPV1 | |
| SCHEMBL3233075 | 0.77 | GALR2 (0.81) | TRPV1 | |
| SCHEMBL6789606 | 0.77 | CYBB (0.49) | — | |
| SCHEMBL6788466 | 0.76 | HRH4 (0.44) | — | |
| SCHEMBL5445460 | 0.76 | TRPV1 (0.59) | TRPV1 | |
| SCHEMBL5455407 | 0.76 | GALR2 (0.68) | TRPV1 | |
| SCHEMBL14418936 | 0.74 | TRPV1 (0.83) | TRPV1 | |
| SCHEMBL3877364 | 0.74 | GALR2 (0.56) | TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6936607-B2 | 2,4,6-Triaminopyrimidines for the treatment of depression and/or anxiety | H. LUNOBECK A/S (DK) | 2005-08-30 | — | — | US | disclosed |
| US-20040127502-A1 | Use of GAL3 antagonist for treatment of depression | SYNAPTIC PHARMACEUTICAL CORPORATION | 2004-07-01 | — | — | US | disclosed |
| US-20040082587-A1 | 2,4,6-Triaminopyrimidines for the treatment of depression and/or anxiety | H. LUNDBECK A/S (DK) | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082587-A1 | 2,4,6-Triaminopyrimidines for the treatment of depression and/or anxiety | GALR3, GALR2, GALR1 | TRPV1 584/4885 |
| US-20040127502-A1 | Use of GAL3 antagonist for treatment of depression | GALR3, GALR2, GALR1 | TRPV1 500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.